23:17 , Jun 20, 2019 |  BC Extra  |  Company News

Spero's TB program first licensing deal for Gates Medical Research Institute

A partnership to develop Spero's Phase I compound for tuberculosis is the first licensing deal announced by Gates MRI, the translational research institute launched by the Bill & Melinda Gates Foundation in 2017. Spero Therapeutics...
23:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
19:47 , Mar 19, 2019 |  BC Extra  |  Tools & Techniques

FNIH launches project to improve TB vaccination

Backed by the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health launched a project to study a new delivery route to improve the efficacy of the only approved tuberculosis vaccine....
19:40 , Mar 19, 2019 |  BC Extra  |  Politics & Policy

FDA issues guidances for long-acting PrEP, pediatric HIV drug development

FDA released final versions of two guidances Tuesday aimed at developing drugs for pediatric HIV patients and for pre-exposure prophylaxis (PrEP), which HHS Secretary Alex Azar said was in line with the Trump administration's HIV...
23:55 , Mar 14, 2019 |  BC Week In Review  |  Company News

AbCellera, Gates Foundation partner on infectious disease treatments

Antibody company AbCellera partnered with the Bill & Melinda Gates Foundation to develop vaccines and antibody-based therapies to treat infectious diseases. AbCellera Biologics Inc. (Vancouver, B.C.) will receive $4.8 million in funding for the two-year...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
12:04 , Jan 29, 2019 |  BC Extra  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
15:52 , Jan 24, 2019 |  BC Extra  |  Politics & Policy

Report: Global increase in R&D for neglected diseases

Global R&D funding for neglected diseases reached a new peak of $3.57 billion in 2017, according to a new report from Policy Cures Research Ltd. (Sydney, Australia). The total was $232 million higher than the...
22:40 , Jan 23, 2019 |  BC Innovations  |  Translation in Brief

Partners in Neglected Infections

Collaborations between two companies and two Liverpool-based institutes have yielded new compounds targeting bacteria in the genus Wolbachia that could treat onchocerciasis and lymphatic filariasis faster and help prevent transmission more effectively than available therapies....